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Objectives: Malignant pleural effusion (MPE) means poor prognosis in the majority of cases. In-
trapleural Hyperthermic perfusion chemotherapy (HIPEC) looks promising approach for these
patients. We aimed to investigate whether cytoreductive surgery followed by HIPEC provides
any survival benefit in cases with metastatic MPEs.
Methods: Between January 2009 and December 2011, 19 patients with metastatic MPEs were
treated with HIPEC following surgical interventions such as pleurectomy/decortication and/
or lung resection (Group 1). Comparison was done with historical control groups consisted of
patients who received either talc pleurodesis or pleurectomy/decortication followed by sys-
temic treatment for the management of metastatic MPEs between June 2007 and June 2008
(group 2 and 3). Statistical analyses including overall survival, disease free interval were done
for the group comparisons.
Results: Median survival in group 1, 2 and 3 were 15.4, 6, 8 months, respectively. One year sur-
vival was 54.7% in group 1 where it was 0.6% and 0.8% in group 2 and 3, respectively. There was
no operative mortality. Morbidity was occurred in 1 patient in group 1 (5.3%).
Conclusions: HIPEC combined with cytoreductive surgery seems to be a promising treatment op-
tion for subjects with metastatic MPEs. Further studies are needed for the optimization of HIPEC
method, drug of choice, and the best combination therapy for the multimodal treatment.
ª 2013 Elsevier Ltd. All rights reserved.23643767.
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first therapeutic intervention as cytoreduction plus HIPECMalignant pleural effusion (MPE) is not a rare entity faced by
pulmonary clinicians and thoracic surgeons.1,2 The meta-
static malignancies of pleura are more common than its
primary tumors. Lung cancer is the most common primary
neoplasm metastasizes to pleura followed by breast cancer
and lymphoma.3 Current treatment options of malignant
pleural effusions are limited to supportive care in the ma-
jority of patients. MPE related to lung carcinoma means
a median survival of 4e6 months despite using multimodal
treatments including surgery, chemotherapy and radio-
therapy.4 Therefore, new therapeutic options are needed.
It has been suggested by Giovanella and colleagues that
hyperthermia itself is tumoricidal.5 Exposure to tempera-
tures of 42.5e43 C for 4e8 h has been shown to have
significantly greater lethal effect on the tumor cells com-
pared to non-neoplastic cells in cell culture models. It has
also been shown that hyperthermia increase the cytotox-
icity of many chemotherapeutic agents in human cell cul-
ture models and animal models.6,7
Spratt and colleagues pioneered a system to deliver hy-
perthermic chemotherapy to the peritoneal cavity in a canine
model and in human in 1980.8 This was followed by several
studies using similar systems to perform hyperthermic per-
fusion chemotherapy (HIPEC) to the peritoneal cavity in sub-
jects with abdominal cancers including malignant peritoneal
mesothelioma.9e11 These studies reported significant survival
advantage of intraperitoneal HIPEC compared to standard of
care. These optimistic results lead researchers to investigate
whether intrapleural (IP) HIPEC works in subjects with ma-
lignant pleural effusion. Although there are limited data, IP
HIPEC in malignant pleural effusions looks promising.12,13
In this study, we aimed to investigate the survival and
disease free interval in subjects with metastatic pleural
malignancies who underwent IP HIPEC in addition to
cytoreduction.
Materials and methods
The hospital records of the subjects with malignant pleural
effusion who admitted to Department of Thoracic Surgery of
Gaziantep University Hospital between January 2009 and
December 2011 were reviewed in a retrospective manner.
The patients who underwent IP HIPEC in addition to cytor-
eduction for the management of metastatic MPE were inclu-
ded in group 1. Another two groups of patientswith secondary
MPE who have been investigated in our previous study were
included as the historical control groups and defined as group
2 and 3.14 Subjects in group 2 received talc pleurodesis and
subjects in group 3 received pleurectomy/decortication by
video assisted thoracic surgery (VATS) for the management of
metastatic MPE. All of the subjects in groups received sys-
temic chemotherapy following pleural interventions. Selec-
tion criteria were as follows: subjects withmetastatic pleural
malignancies proved by pleural cytology and/or biopsy,
subjects with good performance status, subjects with lung
cancer and no distant metastasis except pleura, subjects
with lung cancer and nodal status of N1 or less. Informed
consent formswere signed by all subjects. The study protocol
was approved by institutional Ethics Committee.Overall survival defined as the period from the date of the
and pleurodesis to the date of death. Disease free interval
was accepted as recurrence of malignant pleural effusion
proved by cytological or histopathological examination.
Cytoreduction in group 1 was performed as pleurectomy
and decortication in all subjects. Additionally lung and
adjacent structures were resected if possible. Parietal,
mediastinal and diaphragmatic pleura were resected. Only
in one patient, diaphragma had to be resected in order to
provide maximum cytoreduction. Large bore (28e32 F)
chest tubes were inserted at the end of surgery before the
thoracic cavity was closed. HIPEC was performed through
these chest tubes. HIPEC was applied intraoperatively using
a perfusator (Rand Performer LRT-Medolla/Italy). The
temperature was set to 42 C, and the intrapleural perfusion
was first started with 0.9% sodium chloride isotonic solution.
During the IP lavage, the effected lung was allowed to be
half inflated and the lavage was continued until perfusate
(0.9% sodium chloride isotonic solution) comes from the exit
tube. The volume of saline used was ranged between 1500
and 3200 mL with 1e1.2 L/min flow rate. This stage took
about 1 h. Then IP HIPEC was performed by using 300 mg/m2
of Cisplatin for 60 min. In order to protect brain from the
side effects of hyperthermia, ice bags were placed around
patient’s head during intrapleural perfusion. Hydration with
50 mL/kg/24 h saline, dextrose solution and fresh frozen
plasma was performed in all subjects in order to prevent
renal complications in the postoperative 24 h. Oral intake
was begun on the first postoperative day.
Selection criteria were as follows: subjects with meta-
static pleural malignancies proved by pleural cytology and/
or biopsy, subjects with good performance status, subjects
with lung cancer and no distant metastasis except pleura,
subjects with lung cancer and nodal status of N1 or less. All
subjects over 20 years old diagnosed to have metastatic MPE
during the study period were included. Malignant pleural
effusionwas definedas exudative pleural effusion associated
with one of the followings: positive cytology/histopathology
for malignancy, known primary cancer without co morbid
conditions which may cause exudative pleural effusion.
Talc pleurodesis was performed through a small bore
chest tube (Pleurocan, B. Brown, Melsungen, Germany) in
the form of slurry (4.5 g talc in/100 ml saline solution).
VATS pleurectomy was performed as follows: all apical
and basal parts of parietal pleura were excised except
mediastinal and diaphragmatic sides under general
anesthesia.
All subjects in groups received systemic chemotherapy
planned according to primary cancer. The systemic che-
motherapy protocols were cisplatin based in all subjects.
Interventional, histopathological data and chemotherapy
protocols were given in Table 1.Statistical analysis
The KaplaneMeier method was used to estimate the sur-
vival curve. Log rank (Mantel-cox) was used for comparison
of groups. SPSS version 17 (SPSS Science, Chicago, Illinois)
was used for the statistical calculations. p < 0.05 was
accepted as significant in group comparisons.
Table 1 Histopathology, type of surgery, systemic treatment, and survival data in Group 1.
Patient
numbers
Histopathology/Primary region Surgery Rad Survival
1 Rabdomyosarcoma Met.
(Right leg operated in 2007)
R Vats þ P  Ex. 14th M
2 Adenocarcinoma (LC) R T þ P  Ex. 8th M
3 Adenocarcinoma (LC) R T þ P/D  Ex. 1st M
4 Adenocarcinoma (LC) R Vats þ P/D þ Ex 27th M
5 Malign Epitelial Tm
(Large cell Neuroendocrine
Carcinom) (LC)
R Pneumonectomy þ P/D  Ex. 2nd M
6 Adenocarcinoma (LC) L T þ P/D þ Ex. 3rd M
7 Adenocarcinoma (LC) R T þ P/D þ Ex. 16th M
8 Malign Fibrouse Histiocitoma
(Right gluteal muscle)
LLL þ P/D þ completion
pneumonectomy þ Diaph. Res.
þ Ex. 8th M
9 Adenosquamous carcinoma (LC) L T þ P/D  Alive 30th M
10 Met.Adenocarcinoma (GIS) R T þ P/D  Ex. 9th M
11 Malign Tm (Colon) R T þ Pars.Decort.  Ex. 6th M
12 Malign Mesenchyimal Tm
(Secondary to radiotherapy
after operated Breast CA.)
R T þ CWR þ Pulm. Wedge Res. þ Ex. 17th M
13 Adenocarcinoma (LC) L T þ P/D þ Alive 22nd M
14 Timoma B2 Extended Thymectomy þ P/D þ Alive 22nd M
15 Adenocarcinoma (LC) R T þ UL Wedge rez þ P/D þ Alive 18th M
16 Adenoacrcinoma (LC) L Pneumectomy þ P/D þ Alive 18th M
17 Osteosarcoma Met (left femoral
region)
LLL þ P/D (Second Line: R T
þ Wedge rez.)
 Alive 16th M
18 Adenocarcinoma (LC) R T þ LL þ P/D þ Alive 8th M
19 Adenocarcinoma (LC) L T þ P/D þ Alive 7th M
R: right, RT: right thoracotomy, LT: left thoracotomy, P/D: Pleurectomy/decortication; CWR: Chest wall resection; UL: Upper lobec-
tomy; LL: Lower lobectomy; GIS: Gastro intestinal system; LLL: Left lower lobectomy, Systemic chemotherapy included
Cisplatin þ vinoralbine, Taxol þ gemcitabine, Carboplatin þ gemcitabine, Cisplatin þ pemetrexate and Carboplatin þ pemetrexate.
Rad: radiotherapy.
Table 2 Primary origin of tumors in groups.
Group/primary side Group 1 Group 2 Group 3 Group 4
Lung cancer 12 3 7 22
Over Ca e 4 3 7
Endometrium Ca e 2 e 2
GIS þ colon 2 1 1 4
Malign mesenchymal 4 e e 4
Malign thymoma 1 e e 1
Pancreas Ca e 1 1
Bile cyst Ca e e 1 1
Renal cell Ca e 1 e 1
Non-Hodgkin
Lymphoma
e 1 e 1
Gender male 14 6 7 27
Gender female 5 7 5 17
Total 19 13 12 44
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Group 1 included 19 patients with mean age of 53.4 (14
male and five female). Group 2 included 13 subjects with
mean age of 54.3 (6 male and 7 female). Group 3 included
12 subjects with mean age of 55.6 (7 male and 5 female).
A total of 21 surgical interventions were performed in 19
patients (Table 1). Two patients needed second resection
(completion pneumonectomy and wedge resection) due to
recurrences. Overall, two lobectomies, three pneumonec-
tomies and 16 pleurectomy/decortication were performed.
The primary origins of tumors in treatment groups were
shown in Table 2.
Median survival in group 1, 2 and 3 were 15, 6, and 8
months respectively (Fig. 1). One year survival was 54.7% in
group 1 while it was 0.6% and 0.8% in group 2 and in group 3,
respectively (p < 0.01 and p < 0.05). Overall survival was
not different between group 2 and group 3. The subgroup
analysis for the comparison of survival between cases with
primary lung carcinoma in treatment groups showed that
overall survival was significantly longer in those cases in
group 1 (p < 0.05) (Fig. 2). On the other hand, seven out of
19 patients had MPE with primary tumor other than lung
carcinoma. Primary tumors in these cases were as follows:
malignant mesenchymal tumors in four cases, digestivecanal tumors in two cases, and malignant thymoma in one
patient. Twelve and 15 months survival in this subgroup was
found to be 57.1% and 42.9%, respectively. Two patients
died in this subgroup and both of them were malignant
mesenchymal tumors.
No intraoperative mortality was experienced in group 1.
Specific complication due to IP HIPEC was occurred in one
Figure 1 Survival probability of subjects in groups (1: HIPEC
group; 2 and 3: Talk pleurodesis and VATS pleurectomy groups
respectively) (p < 0.01 and p < 0.05).
Figure 2 Intergroup comparison of survival between subjects
with lung cancer (1: Lung cancer in HIPEC group; 2: Lung
cancer in groups 2 and 3): The survival was significantly longer
in subjects with lung cancer in group 1 compared to group 2
and group 3 (p < 0.05).
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atinine level observed in the postoperative day 3rd. The
plasma creatinine level was decreased to normal following
intravenous fluid therapy. Postoperative chylothorax was
developed in the same case for days after surgery and
resolved with low fat diet and chest drainage. The pleural
effusion three days following surgery was reaccumulated in
one patient with the primary cancer of gastro intestinal
adenocarcinoma. Cytopathological examination revealed
benign effusion and improved after drainagewith pleurocan.Discussion
This study shows that IP HIPEC in combination with cytor-
eduction provides significantly better survival compared to
those who received either pleurectomy or talc pleurodesis
for the management of metastatic pleural malignancies.
Intrathoracic space is covered by a serous membrane,
called pleura, and plays a preventing role for disease
expansion from one side to other. Nearly all malignant tu-
mors (solid tumors and hematologic malignancies) may
spread to the pleural surface.15 Either primary or meta-
static pleural cancers have bad prognosis and short survival
expectation so that there is no standard approach for
treatment.4 Median survival following diagnosis ranges from
3 to 12 months and is depended on the stage and the type of
the underlying malignancy.16 Survival in MPE is the shortest
in subjects with primary lung cancer while it was the lon-
gest in subjects with primary ovarian cancer. Currently,
palliative therapy either with pleurodesis or pleurectomy/
decortication is the choice of treatment in secondary
MPEs.17 Other treatment approaches are chemotherapy
and/or radiotherapy. Unfortunately, none of these ap-
proaches provides a significant benefit for the survival. In
the present study median survival was found to be 15.6
months in group 1 (HIPEC group) where it was 6 months in
group 2 (talc group) and 8 months in group 3 (pleurectomy
group). One year survival was found to be 54.7% in group 1
compared to 0.6% in group 2 and 0.8% in group 3.
MPE associated with primary lung carcinoma has the
worst survival. There are few studies in English literature
reported the results of IP HIPEC in MPEs associated with
primary lung carcinoma.12,18,19 Shigemura et al.12 used IP
HIPEC through thoracoscope before pleuropneumonectomy
in 5 non-small cell lung cancer patients with pleural
involvement. Thoracotomy for pleuropneumonectomy was
performed immediately flowing IP HIPEC for each subject.
They reported mean survival of 19 months. They also
stressed that four patients were still alive when the article
was published and the longest survival was 32 months.
Kodoma et al.18 applied IP HIPEC in 26 cases of lung carci-
noma with pleural involvement 10e14 days after pulmonary
resection and reported 5 year cumulative survival of 24.6%.
Twenty-four of these patients had an initial diagnosis of
pleural involvement at thoracotomy. The other seven pa-
tients had massive malignant effusion at the time of the
initial diagnosis. Local relapse free survival was found as
76.3%. Additionally, negative mediastinal lymph node
involvement revealed much longer survival. Three and 5
year survival were as 68.4% and 42.7%, respectively. How-
ever, even if in the patients with mediastinal lymph node
766 A.F. Is‚ık et al.involvement, they found 3 year survival rate as 22.7%. Ac-
cording to us, these results show support the benefit of the
hyperthermic perfusion after surgical interventions. Mat-
suzaki et al.19 reported median survival of 20 months in
subjects who received pulmonary resection followed by IP
HIPEC compared to six months in subjects who received
only pulmonary resection for the treatment of lung cancer
with pleural involvement, although, the difference in sur-
vival was not statistically significant between two groups. In
the present study, there were twelve cases of primary lung
carcinoma with MPEs. Among these cases, 6 died and 6
cases were still alive during the writing process of this
article. The survival time for these 6 patients was ranged
between seven and 30 months. Although, there are meth-
odological differences in these studies the IP HIPEC treat-
ment looks promising in pulmonary carcinoma with pleural
involvement.
There are limited data on the effects of IP HIPEC in
metastatic MPEs associated with primary cancers other
than lung carcinoma. Refaely et al.20 reported the results
of IP HIPEC on 15 subjects of thymic malignancies with
pleural spread. They performed IP HIPEC in all subjects
while they performed resection without pleurectomy in 9
patients, resection with pleurectomy in 5 patients, and
extrapleural pneumonectomy in 1 patient. They reported
survival of 7e70 months in these subjects. They concluded
that IP HIPEC along with cytoreduction seems to offer
excellent local control for patients with stage IV-a thymic
malignancies and may lengthen survival in stage IV-
a thymoma. In the present study, seven out of 19 patients
had MPE with primary tumor other than lung carcinoma.
Twelve and 15 months survival were 57.1% and 42.9%,
respectively.
The cisplatin is one of the most preferred agents for IP
HIPEC due to its direct cytotoxic activity.21 Cisplatin dosage
during IP HIPEC was ranged between 50 mg/m2 and 400 mg/
m2 in various studies.12,19,21e26 Several toxic side effects
related to intrapleural cisplatin dose have been reported by
previous studies. Nephrotoxicity is the major concern to
prevent using high dose of cisplatin during IP HIPEC. How-
ever, increase in dosage of cisplatin gets longer survival
time in patients. Richards et al. studied the dosage cis-
platin between 50 and 250 mg/m2 and found that patients
treated with 250 mg/m2 cisplatin had much longer survival
time.25 For this reason we preferred to apply 300 mg/m2 of
IP cisplatin to all subjects. Only one patient had a moderate
increase in urea and creatinine levels and it was success-
fully managed by intravenous fluid treatment without any
complication.
There are certain limitations to this study. First of all
this is a retrospective study with low number of subjects.
Secondly, the historical control groups used for the
comparison of survival in different groups. Finally, there
was no homogeneity in the origins of primary tumors in the
groups.
In conclusion, cytoreduction followed by IP HIPEC looks
promising to provide better survival compared to talc
pleurodesis or pleurectomy/decortication in the manage-
ment of metastatic MPEs. Larger studies needed for the
optimization of IP HIPEC method, the dosage and the type
of chemotherapeutic agent and the best combination
therapies in addition to IP HIPEC.Conflict of interest
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